| Jennifer Lewin, | |
|
809 82nd Pkwy, Myrtle Beach, SC 29572-4607 | |
| (843) 692-1000 | |
| Not Available |
| Full Name | Jennifer Lewin |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 809 82nd Pkwy, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104485382 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | R203631 (Maryland) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 23027 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mcleod Loris Hospital | Loris, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcleod Physician Associates Ii | 8224031307 | 520 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
| Entity Name | Coastal Anesthesia Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609813179 PECOS PAC ID: 1850295650 Enrollment ID: O20031124000145 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
| Entity Name | Mcleod Physician Associates Ii |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801990494 PECOS PAC ID: 8224031307 Enrollment ID: O20060926000568 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
| Entity Name | Beach Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215061429 PECOS PAC ID: 6103924014 Enrollment ID: O20070530000620 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
| Entity Name | Mcleod Loris Seacoast Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265708119 PECOS PAC ID: 9133394398 Enrollment ID: O20120710000230 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Lewin, 2404 Chestnut Terrace Ct Unit 302, Odenton, MD 21113-4128 Ph: () - | Jennifer Lewin, 809 82nd Pkwy, Myrtle Beach, SC 29572-4607 Ph: (843) 692-1000 |
News Archive
Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
In an article examining recent developments at the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Wall Street Journal interviews Gabriel Jaramillo, the Colombian-born Brazilian citizen and former CEO of Sovereign Bank who will become the fund's new general manager this week.
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company has entered into a partnership with American HealthCare Lending to provide funding for patient access to vBloc Therapy, delivered via the Maestro Rechargeable System, for the treatment of obesity.
One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen treatment failure.
Illumina, Inc. today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed.
› Verified 6 days ago
Travis Mills, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2432 Hunters Trl, Myrtle Beach, SC 29588 Phone: 423-736-0357 | |
Patrick E Quinn, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Jane I Dickman, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Jean M. Vinski, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Deborah Marie Rambo, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Anesth Dept, Myrtle Beach, SC 29572 Phone: 843-692-1000 | |
Debra K Hamerski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7900 N Kings Hwy, Myrtle Beach, SC 29572 Phone: 843-449-3381 | |
Irina Walker, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-602-2408 |